Abbott Laboratories
ABT
Below: live stock price for Abbott Laboratories (ABT), a 1-year chart, 8 indicators (RSI, MACD, Bollinger, MA, EMA, Stochastic, ATR, Volume), and a compare mode. Add to your portfolio, star to your watchlist, or set a price alert in one place.
- Prev close
- $86.99
- Volume
- $14.12M
- Market cap
- $158.12B
- Currency
- USD
Financials
- 52w high
- $139.06
- 52w low
- $81.97
- 52w change
- -35.05%
- Day high
- $91.48
- Day low
- $89.20
- P/E (TTM)
- 25.43
- Forward P/E
- 14.98
- PEG
- 1.29
- Price / Book
- 3.04
- Beta (5Y)
- 0.65
- Enterprise value
- 185.6B
- EV / Revenue
- 4.11
- EV / EBITDA
- 15.8
- EPS (TTM)
- $3.57
- Forward EPS
- $6.06
- Dividend yield
- 2.78%
- Dividend rate
- $2.52
- Payout ratio
- 67.23%
- Revenue (TTM)
- 45.13B
- EBITDA
- 11.74B
- Free cash flow
- 6.34B
- Total cash
- 7.3B
- Total debt
- 34.14B
- Debt / Equity
- 64.77
- Current ratio
- 1.39
- Quick ratio
- 0.84
- Profit margin
- 13.90%
- Gross margin
- 56.50%
- Return on assets
- 5.59%
- Return on equity
- 12.33%
- Shares outstanding
- 1.74B
- Float
- 1.73B
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
Analyst & Risk
- Beta (vs S&P 500)
- 0.65
- less volatile
- 52-week change
- -35.05%
- Short % of float
- 1.49%
- Short ratio (days)
- 1.63
- Debt / Equity
- 64.77
- very high leverage
- Current ratio
- 1.39
- Quick ratio
- 0.84
- ROE
- 12.33%
- ROA
- 5.59%
- PEG ratio
- 1.29
- fair
- EV / Revenue
- 4.11
- EV / EBITDA
- 15.8
- Revenue growth
- 7.80%
- Earnings growth
- -19.70%
- EBITDA
- 11.74B
- Free cash flow
- 6.34B
- Total cash
- 7.3B
- Total debt
- 34.14B
- Insider holdings
- 0.49%
- Institutional
- 82.66%
Recent rating changes
- 2026-04-27BTIGBuy → Buyreit
- 2026-04-20BarclaysOverweight → Overweightmain
- 2026-04-17Piper SandlerOverweight → Overweightmain
- 2026-04-17OppenheimerOutperform → Outperformmain
- 2026-04-17RBC CapitalOutperform → Outperformmain
- 2026-04-17BenchmarkBuy → Buymain
- 2026-04-17Evercore ISI GroupOutperform → Outperformmain
- 2026-04-17B of A SecuritiesBuy → Buymain
Financial documents
- Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)SD2026-05-27
- Periodic Financial Reports10-Q2026-04-29
- Corporate Changes & Voting Matters8-K2026-04-27
- Offering RegistrationsS-82026-04-24
- Corporate Changes & Voting Matters8-K2026-04-17
- Corporate Changes & Voting Matters8-K2026-04-16
- Offering RegistrationsS-82026-03-23
- Proxy StatementsDEFA14A2026-03-13
- Corporate Changes & Voting Matters8-K2026-03-09
- Corporate Changes & Voting Matters8-K2026-02-26
- Periodic Financial Reports10-K2026-02-20
- Corporate Changes & Voting Matters8-K2026-01-22
Recent news
- Abbott Addresses a Major Diabetes Care Gap With Tech InnovationZacks13h ago
- Jim Cramer Says “No One Disputes the Science and Commercial Smarts of Abbott”Insider Monkey16h ago
- Assessing Abbott Laboratories (ABT) Valuation After New Diabetes Sensor And Cancer Screening TailwindsSimply Wall St.1d ago
- Medtronic Stock Is Defying a Market Selloff After Earnings. Here’s Why.Barrons.com1d ago
- MiniMed Expands Abbott Partnership to Commercialize Dual Glucose-Ketone SensorsMT Newswires1d ago
- QuidelOrtho's Respiratory Exposure Remains a Key Near-Term RiskZacks1d ago
- Insulet Rolls Out Omnipod 5 With Enhanced Algorithm, Abbott Libre 3 Plus CompatibilityMT Newswires1d ago
- How A Steady Valuation Is Shaping The Evolving Abbott Laboratories (ABT) Investment StorySimply Wall St.2d ago
Live discussion
Sign in to join the discussion.
- No comments yet. Be the first.